Status:
COMPLETED
Study Evaluating ERB-041 in Active Crohn's Disease
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Crohn's Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Evaluate the response of inflammatory serum markers to oral ERB-041 in subjects with inflammation associated with active Crohn's disease.
Eligibility Criteria
Inclusion
- Men and women, minimum 18 years of age with a diagnosis of Crohn's disease greater than 3 months,
- Eligible subjects must have adequate hematologic, renal, and hepatic function.
- Other inclusions apply
Exclusion
- Use of the following medications within the specified time period before randomization is prohibited:
- Within 48 hours before randomization
- Nonsteroidal antiinflammatory drugs (NSAIDs) Within 2 weeks before randomization
- Herbal supplements (except for a daily multivitamin/mineral supplement not containing herbal components).
- Other exclusions applies
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2005
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00245947
Start Date
April 1 2004
End Date
April 1 2005
Last Update
September 10 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.